Sigal Charles Elliott is a director of Surface Oncology, Inc.
Person profile
Roles
Surface Oncology
Director
Adaptimmune Therapeutics
Director
Vir Biotechnology
Director
Alnylam Pharmaceuticals
Director
Address
Princeton, New Jersey
Employees
SEC CIK
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Surface Oncology, Inc.
8 Sep 23
4
Adaptimmune Therapeutics PLC
3 Jul 23
4
Vir Biotechnology, Inc.
24 May 23
4
ALNYLAM PHARMACEUTICALS, INC.
19 May 23
4
Vir Biotechnology, Inc.
2 Mar 23
4
Vir Biotechnology, Inc.
9 Jan 23
4
Vir Biotechnology, Inc.
5 Jan 23
4
ALNYLAM PHARMACEUTICALS, INC.
24 Aug 22
3
ALNYLAM PHARMACEUTICALS, INC.
24 Aug 22
4
Adaptimmune Therapeutics PLC
1 Jul 22
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Sep 23 | SURF Surface Oncology | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 45,453 | 0.00 | 0 |
8 Sep 23 | SURF Surface Oncology | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.35 | 113,636 | 39.77 k | 0 |
3 Jul 23 | ADAP Adaptimmune Therapeutics | Option to purchase Ordinary Shares Ordinary Shares | Grant | Acquire A | No | No | 0.16 | 933,317 | 149.33 k | 933,317 |
22 May 23 | VIR Vir Biotechnology | Common Stock | Grant | Acquire A | No | No | 0 | 6,027 | 0.00 | 15,806 |
22 May 23 | VIR Vir Biotechnology | Stock Option Common Stock | Grant | Acquire A | No | No | 25.74 | 12,054 | 310.27 k | 12,054 |
18 May 23 | ALNY Alnylam Pharmaceuticals | Stock Option Common Stock | Grant | Acquire A | No | No | 189.87 | 3,454 | 655.81 k | 3,454 |
1 Mar 23 | VIR Vir Biotechnology | Common Stock | Buy | Acquire P | Yes | Yes | 22.7262 | 2,500 | 56.82 k | 10,000 |